Ansari et al. [47] found that high TPMT activity (> 14 u/mL) was significantly associated with non-response in AZA-treated IBD patients (OR 0.21, 95% CI 0.07–0.68). The gene discussed is TPMT; the disease is inflammatory bowel disease.